Delivery Order SPE2DR25D3017-SPE2DR26F3GD4
- Not listed
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a firm fixed-price delivery order by the Defense Logistics Agency on January 27, 2026, for Lantus SoloStar 100 Unit/mL 3mL insulin pens with a ceiling value of $1,286.98. This is a non-set-aside competitive award with an ultimate completion date of January 28, 2026, and performance to be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a task order issued under...
- AmerisourceBergen Drug Corp has been awarded a competitively competed delivery order by the Defense Logistics Agency (DLA) for Lantus SoloStar 100 Unit/ML insulin pens, valued at $1,294.28. The order, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery requirement from its corporate office location....
- AmerisourceBergen Drug Corp was awarded a $1,197.07 firm fixed-price delivery order by the Defense Logistics Agency on July 18, 2025, for Lantus SoloStar 100 Unit/ML 3ML insulin pens. This is a non-set-aside competitive award with an ultimate completion date of July 21, 2025, with performance taking place at the contractor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 28, 2026, for Lantus SoloStar 100 Unit/mL 3mL insulin pens, valued at $2,018.11. The award is a firm fixed-price delivery order with no set-aside designation, indicating competitive procurement. Performance will be executed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 29, 2026....
- This delivery order, awarded on January 20, 2026, is for Lantus SoloStar 100 Unit/mL insulin pens valued at $1,168.14 and issued to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA). The order represents a competitive award with no set-aside designation and carries a firm fixed-price structure with an ultimate completion date of January 21, 2026. AmerisourceBergen, operating under parent company Cencora, Inc., serves as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a $2,348.65 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,503.87 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This competitively awarded, non-set-aside contract operates under a firm fixed price structure with an ultimate completion date of November 17, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens, valued at $1,312.94. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of December 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across...
- Amerisourcebergen Drug Corp has received a $5,935.32 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply Lantus SoloStar 100 unit/ml pre-filled insulin pens. The delivery order was awarded against an existing, indefinite-delivery contract with no set-aside designation specified. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania, with completion by November 1, 2023. As a leading pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $1,996.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with an ultimate completion date of October 29, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which runs through December 2026. AmerisourceBergen, headquartered in...
- SPE2DR25D3017Indefinite Delivery Contract
- SPE2DR25D3017-SPE2DR26F3GD4Delivery Order
AmerisourceBergen Drug Corp (child entity of Cencora, Inc.) received a firm fixed-price delivery order from the Defense Logistics Agency (DLA) valued at $1,563.40 for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with a completion date of February 3, 2026. The award was made on a fully competitive, non-set-aside basis to support federal medical supply requirements. Performance will occur at the contractor's Conshohocken, Pennsylvania facility, which serves as the corporate headquarters for this major pharmaceutical distributor serving military and federal healthcare systems. This delivery order is executed under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026. This comprehensive IDC enables the contractor to supply a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices to support global military healthcare programs. The contract demonstrates AmerisourceBergen's established capability to efficiently fulfill federal pharmaceutical procurement requirements and support the Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 2/1/26 |